Enzo Biochem 8-K: Acquisition, Delisting Notice, Control Change
| Field | Detail |
|---|---|
| Company | Enzo Biochem Inc |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | high |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.01, $0.70 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, delisting, change-of-control, corporate-action
TL;DR
Enzo Biochem 8-K: Big changes coming - acquisition, possible delisting, new bosses, and bylaws tweaked.
AI Summary
Enzo Biochem, Inc. filed an 8-K on August 20, 2025, reporting several material events. These include the completion of an acquisition or disposition of assets, a notice of delisting or failure to meet listing standards, material modifications to security holder rights, and changes in control of the registrant. The filing also details departures of directors or officers, election of directors, appointment of officers, and compensatory arrangements. Additionally, amendments to articles of incorporation or bylaws and changes in the fiscal year are noted, along with financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions at Enzo Biochem, including potential delisting and changes in control, which could materially impact its stock and operations.
Risk Assessment
Risk Level: high — The filing indicates multiple significant events including a notice of delisting, changes in control, and asset disposition, suggesting substantial operational and financial uncertainty.
Key Players & Entities
- Enzo Biochem, Inc. (company) — Registrant
- August 20, 2025 (date) — Date of earliest event reported
- 0001213900-25-078736 (accession_number) — Filing accession number
FAQ
What specific assets were acquired or disposed of by Enzo Biochem?
The filing does not specify the exact assets involved in the acquisition or disposition.
What are the reasons for the notice of delisting or failure to satisfy listing rules?
The filing does not detail the specific reasons for the notice of delisting or failure to satisfy listing rules.
What changes in control of Enzo Biochem are being reported?
The filing indicates a change in control but does not provide specific details about the parties involved or the nature of the change.
Were there any departures or appointments of key officers or directors?
Yes, the filing reports departures of directors or certain officers, election of directors, and appointment of certain officers, along with compensatory arrangements.
Are there any amendments to Enzo Biochem's articles of incorporation or bylaws, or a change in fiscal year?
Yes, the filing indicates material modifications to rights of security holders and potential amendments to articles of incorporation or bylaws, as well as a change in fiscal year.
Filing Stats: 1,734 words · 7 min read · ~6 pages · Grade level 11.3 · Accepted 2025-08-20 08:21:27
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ENZB OTC Markets OTCQX
- $0.70 — lly converted into the right to receive $0.70 in cash, without interest (the "Merger
Filing Documents
- ea0253697-8k_enzo.htm (8-K) — 54KB
- ea025369702ex3-1_enzo.htm (EX-3.1) — 11KB
- ea025369702ex3-2_enzo.htm (EX-3.2) — 58KB
- 0001213900-25-078736.txt ( ) — 304KB
- enzb-20250820.xsd (EX-101.SCH) — 3KB
- enzb-20250820_lab.xml (EX-101.LAB) — 33KB
- enzb-20250820_pre.xml (EX-101.PRE) — 22KB
- ea0253697-8k_enzo_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZO BIOCHEM, INC. By: /s/ Patricia Eckert Name: Patricia Eckert Title: Chief Financial Officer Date: August 20, 2025 4